iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Savant Capital LLC

Savant Capital LLC lessened its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 15.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,707 shares of the financial services provider’s stock after selling 674 shares during the quarter. Savant Capital LLC’s holdings in iShares Biotechnology ETF were worth $504,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IBB. Bank of New York Mellon Corp lifted its position in shares of iShares Biotechnology ETF by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,146 shares of the financial services provider’s stock valued at $2,586,000 after buying an additional 716 shares in the last quarter. Macroview Investment Management LLC raised its stake in iShares Biotechnology ETF by 5,340.0% in the 3rd quarter. Macroview Investment Management LLC now owns 544 shares of the financial services provider’s stock valued at $67,000 after purchasing an additional 534 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter worth $238,000. CENTRAL TRUST Co boosted its position in iShares Biotechnology ETF by 1.2% during the third quarter. CENTRAL TRUST Co now owns 14,838 shares of the financial services provider’s stock worth $1,815,000 after acquiring an additional 174 shares during the last quarter. Finally, Whittier Trust Co. lifted its stake in iShares Biotechnology ETF by 26.4% in the 3rd quarter. Whittier Trust Co. now owns 6,471 shares of the financial services provider’s stock worth $791,000 after purchasing an additional 1,350 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 1.8 %

Shares of IBB opened at $132.96 on Monday. The firm has a market cap of $7.27 billion, a P/E ratio of 17.35 and a beta of 0.86. The company’s 50-day moving average price is $133.61 and its 200 day moving average price is $130.12. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $141.16.

iShares Biotechnology ETF Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 27th. Stockholders of record on Friday, March 22nd were issued a $0.126 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This represents a $0.50 annualized dividend and a dividend yield of 0.38%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.